Under the terms of the agreement, Takeda will have exclusive access to all drug targets that control blood pressure from Lexicon's Genome5000 program. Takeda will be responsible for screening, medicinal chemistry, preclinical and clinical development, and commercialization of drugs directed against Lexicon's targets, the company said.
Lexicon will receive an upfront payment of $12 million from Takeda for the initial, three-year term of the agreement. Takeda will have the option of extending the discovery portion of the alliance for an additional two years in exchange for further committed funding, Lexicon said. Lexicon will also earn royalties on worldwide sales of drugs commercialized by Takeda.
In the Genome5000 program, Lexicon is using gene knockout technology to discover the function of 5,000 of the most pharmaceutically important genes in the human genome, the company said.